ArticleBlood advances2026

Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Zheng Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.